Impact of COVID-19 on U.S. and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices
Author:
Funder
Biogen
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Link
http://link.springer.com/content/pdf/10.1007/s00415-020-10045-9.pdf
Reference24 articles.
1. Wallin MT, Culpepper WJ, Campbell JD et al (2019) The prevalence of MS in the United States: a population-based estimate using health data. Neurology 92(10):e1029–e1040
2. Statistics Canada. Table 13-10-0467-01 Neurological conditions in household population. https://doi.org/10.25318/1310046701-eng. Accessed 7 May 2020
3. No authors listed. National MS Society. Treating MS. https://www.nationalmssociety.org/Treating-MS/Medications. Accessed 2 May 2020
4. Luna G, Alping P, Burman J et al (2019) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.3365(Epub ahead of print)
5. Willis MD, Robertson NP (2020) Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol 267(5):1567–1569
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Era of COVID-19 in Multiple Sclerosis Care;Neurologic Clinics;2024-02
2. Real-world data on the Immunity Response to the COVID-19 Vaccine among Patients with Central Nervous System Immunological Diseases;Siriraj Medical Journal;2024-02-01
3. Evaluation of risk management in a natalizumab home infusion procedure;Revue Neurologique;2023-10
4. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-03
5. Communication between persons with multiple sclerosis and their health care providers: A scoping review;Patient Education and Counseling;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3